GKB Ophthalmics Q4 FY26: Sales fall, profit turns positive

What the latest numbers indicate

GKB Ophthalmics has reported its consolidated performance for the quarter and year ended March 2026, showing a return to profit for FY26 even as quarterly revenue softened. Consolidated net sales for the March 2026 quarter were reported at Rs 29.79 crore, down 3.97% from Rs 31.02 crore in March 2025. For the full year ended March 2026, sales rose 36.76% to Rs 149.06 crore from Rs 108.99 crore a year earlier.

Profitability data in the provided figures points to a sharp improvement in FY26 versus FY25. Full-year consolidated net profit was reported at Rs 1.22 crore for FY26 versus a net loss of Rs 7.04 crore in FY25. For Q4 (March 2026 quarter), net profit was reported at Rs 0.19 crore. The comparable March 2025 quarter is described in the dataset as a net loss of Rs 3.55 crore, even though some percentage change lines appear inconsistent with the loss description.

Q4 FY26: Revenue down, operating metrics improve

While Q4 sales were lower year-on-year, operating indicators improved on the figures shared. EBITDA for the March 2026 quarter was reported at Rs 3.92 crore versus Rs 2.52 crore in March 2025. Operating profit margin (OPM) for the quarter was reported at 10.31% compared with -9.19% in the year-ago quarter.

The dataset also provides pre-tax profitability markers. Profit before depreciation and tax (PBDT) for Q4 FY26 was reported at Rs 3.37 crore compared with Rs -3.14 crore in Q4 FY25. Profit before tax (PBT) was reported at Rs 2.57 crore versus Rs -3.93 crore in the corresponding quarter last year.

FY26: Return to profit alongside stronger sales

At the full-year level, the company’s consolidated sales growth of 36.76% to Rs 149.06 crore is the most direct driver behind the headline improvement. FY26 OPM was reported at 5.75% versus -2.55% in FY25, indicating profitability recovery over the year.

Full-year PBDT was reported at Rs 8.13 crore for FY26 versus Rs -3.64 crore in FY25, while PBT was reported at Rs 4.89 crore versus Rs -6.73 crore. Net profit for FY26 was reported at Rs 1.22 crore, compared with a net loss of Rs 7.04 crore in FY25.

Board meeting scheduled for May 27, 2026

GKB Ophthalmics has scheduled a Board of Directors meeting for May 27, 2026, at its registered office in Mapusa, Goa. As stated, the meeting has been convened to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.

For investors, this is a standard but important milestone because audited numbers can include final adjustments, disclosures, and notes that help explain the drivers behind quarterly volatility, exceptional items, and segment-level shifts.

Q3 FY26 context: Standalone vs consolidated divergence

Separate unaudited Q3 FY26 figures (quarter ended December 31, 2025) show a notable contrast between standalone and consolidated trends. On a standalone basis, the company reported a profit of Rs 0.98 crore versus a loss of Rs 0.17 crore in the corresponding quarter last year. Standalone revenue from operations was reported at Rs 4.36 crore versus Rs 7.45 crore, a decline of 41.4%.

The improvement in standalone profitability was shown alongside a sharp rise in other income, reported at Rs 3.54 crore. Total standalone income for Q3 FY26 was reported at Rs 7.90 crore versus Rs 9.26 crore in Q3 FY25.

On a consolidated basis for Q3 FY26, revenue was reported at Rs 56.79 crore compared with Rs 25.80 crore in Q3 FY25, a 120.1% rise. Consolidated profit was reported at Rs 0.71 crore versus a loss of Rs 1.91 crore in the year-ago quarter, and basic EPS was reported at Rs 0.88 versus Rs -4.03.

Nine-month (9M FY26) performance cited in the dataset

For the nine months ended December 31, 2025, standalone operations were reported to have a loss of Rs 1.68 crore compared to Rs 3.63 crore loss in the corresponding period of FY25. Consolidated nine-month results were reported as a profit of Rs 1.91 crore versus a loss of Rs 2.95 crore in the prior year period.

The dataset also states consolidated revenue for 9M FY26 at Rs 119.27 crore, with a 52.9% increase over the previous year period. Standalone revenue for the same nine-month window was reported at Rs 19.24 crore, down 20.9%.

Key reported financial snapshot (consolidated)

Additional financial and cash flow points disclosed

The provided cash flow table shows net profit or loss before extraordinary items and tax at Rs -6.73 crore for FY25, compared with Rs -2.78 crore for FY24 and Rs 0.14 crore for FY23. Net cash flow from operating activities was reported at Rs -3.43 crore in FY25 versus Rs 4.22 crore in FY24. Net cash used in investing activities was reported at Rs 2.55 crore in FY25 versus Rs -1.71 crore in FY24.

A cost structure datapoint in the dataset notes that, for the year ended March 31, 2025, the company spent 2.18% of its operating revenues towards interest expenses and 15.83% towards employee cost, based on consolidated financials.

Stock price references included in the dataset

The dataset states a current share price of Rs 63.55. It also separately mentions that the share price moved up by 0.81% from its previous close of Rs 64.82. These two references appear as provided and are not reconciled in the source text.

Why this matters for investors tracking small-cap results

The FY26 numbers reported indicate a swing back to profit and a materially stronger revenue base compared with FY25. At the same time, Q4 revenue declined year-on-year, showing that quarterly demand and execution can still be uneven.

The scheduled May 27, 2026 board meeting to approve audited results is the next confirmed event. Investors typically watch audited filings for detailed notes on other income, consolidation drivers, and any exceptional items, especially when quarterly profit moves sharply versus the prior year or when standalone and consolidated trends diverge.

Conclusion

GKB Ophthalmics reported higher FY26 sales and a return to consolidated profitability, while Q4 FY26 saw a modest year-on-year sales decline but improved operating metrics. The company’s next formal update is the May 27, 2026 board meeting to approve audited standalone and consolidated results for the quarter and year ended March 31, 2026.